The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group
J.R. Anderson; J.M. Vose; P.J. Bierman; D.D. Weisenburger; W.G. Sanger; J. Pierson; M. Bast; J.O. Armitage (Profiled Authors: James R Anderson; James Olen Armitage; Philip Jay Bierman; Warren G Sanger; Julie Marie Vose)
Journal of Clinical Oncology 1993;11(2):218-224.Abstract
Purpose: Our purpose was to describe the treatment outcome of patients with follicular large-cell lymphoma (FLCL) and to identify prognostic factors that affect the treatment outcome. Patients and Methods: Between 1980 and 1991, 107 newly diagnosed, previously untreated patients with FLCL were prospectively treated using treatment plans of the Nebraska Lymphoma Study Group (NLSG). Most stage I/II patients received two to three cycles of one of four closely related six-drug combination chemotherapy regimens (cyclophosphamide, doxorubicin or mitoxantrone, and procarbazine, plus bleomycin, vincristine, and prednisone or dexamethasone [CAP/BOP I-IV]) plus involved-field radiotherapy; 10 patients received involved-field irradiation only. Stage III/IV patients received six to eight cycles of CAP/BOP. Results: Forty-four percent of patients had stage I/II disease. Stage I/II patients were older and more often female than stage III/IV patients. Cytogenetic studies were available on 35 patients: seven were normal; the most common abnormality was a translocation involving 14q32. Abnormalities of 1p or 1q were also common, often secondary to a 14q32 abnormality. The median follow- up of surviving patients is 2 years. The complete response rates observed were stage I/II, 88%; stage III/IV, 49%. Complete response rates were affected by both age and tumor bulk. Failure-free survival (FFS; time to first occurrence of progression, relapse after response, or death from any cause) at 3 years was estimated to be 61% for stage I/II patients and 34% for stage III/IV patients. Survival at 3 years was estimated to be 76% and 61%, respectively. FFS of stage III/IV patients was poorer for stage IV patients and those with composite lymphomas. Significantly poorer survival was only seen in patients older than 70 years of age. Conclusion: A proportion of stage I/II FLCL patients may obtain long-term disease control with combination chemotherapy plus radiotherapy. Results for patients with stage III/IV FLCL are similar to those seen for other follicular lymphomas.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
A.K. Ganti; D.D. Weisenburger; L.M. Smith; C.P. Hans; R.G. Bociek; P.J. Bierman; J.M. Vose; J.O. ArmitageAnnals of Oncology 2006;17(6):920-927.
James O. ArmitageMayo Clinic Proceedings 2012;87(2):161-171.
Jeffrey S. Dome; Cecilia A. Cotton; Elizabeth J. Perlman; Norman E. Breslow; John A. Kalapurakal; Michael L. Ritchey; Paul E. Grundy; Marcio Malogolowkin; J. Bruce Beckwith; et al.Journal of Clinical Oncology 2006;24(15):2352-2358.
Appears in this Document